Call Today 888-401-3314

patent Archives

Helsinn Healthcare v. Teva Pharmaceuticals: Complicated Issues Persist in Interpreting the "On-Sale Bar"

On May 1, 2017, the Federal Circuit published its decision in Helsinn Healthcare v. Teva Pharmaceuticals, No. 3:11-cv-03962-MLC-DEA, (May. 1, 2017) concerning infringement of four patents:  U.S. Patent Nos. 7,947,724 ("'724 patent"); 7,947,725 ("'725 patent"); 7,960,424 ("'424 patent") and 8,598,219 ("'219 patent").  Teva defended that the patents were invalid under the "on-sale bar" provision of 35 USC §102.  The District Court held that Teva infringed all of the patents and that the patents were not invalid. Teva appealed. The Federal Circuit reversed the District Court's decision, holding that all four patents were invalid and thus not infringed.

Thales Visionix Inc. v. United States: A Mathematical Equation Does Not Necessarily Doom Claims To Abstraction

On Wednesday, March 8, 2017, the Federal Circuit published its decision in Thales Visionix Inc. v. United States, No. 1:14-cv-00513-TCW, (Mar. 8, 2017) concerning infringement of U.S. Patent No. 6,474,159.  Thales Visionix appealed from the US Court of Federal Claims judgment holding that the claims were directed to patent-ineligible subject matter.  The Federal Circuit reversed the Claims Court's decision and remanded for further proceedings.

Life Technologies v. Promega: The Supreme Court Decision and What it Means to You

On Wednesday, February 22, 2017, the Supreme Court published its decision in Life Technologies Corp. v. Promega Corp. 580 U.S. __ (2017), concerning infringement of US Patent RE 37,984.  The question before the Court was whether supplying a single component of a multicomponent invention overseas constitutes an infringing act under 35 U. S. C. §271(f)(1).

Call 888-401-3314 Or Use Our Contact Form

Bold labels are required.

Contact Information
disclaimer.

The use of the Internet or this form for communication with the firm or any individual member of the firm does not establish an attorney-client relationship. Confidential or time-sensitive information should not be sent through this form.

close

Privacy Policy

Review Us